Aclidinium Bromide (CAS 320345-99-1)
Alternate Names:
(3R)-3-[(2-Hydroxy-2,2-di-2-thienylacetyl)oxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane Bromide; (3R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane Bromide; Aclidinium Bromide; Genuair; LAS 34273; LAS-W 330
CAS Number:
320345-99-1
Molecular Weight:
564.55
Molecular Formula:
C26H30BrNO4S2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Aclidinium bromide is a quaternary ammonium compound extensively studied in the field of respiratory research, particularly for its muscarinic antagonist activity. It is of research interest for its action in inhibiting airway constriction, making it a subject of examination in understanding the regulation of bronchial smooth muscle tone. In cellular studies, aclidinium bromide is used to explore the signaling pathways of muscarinic receptors and their role in pulmonary function. Additionally, this compound is utilized in inhalation technology research due to its physical and chemical properties that affect its distribution and metabolism in the respiratory system. Its stability its local action at the site of deposition are key factors in its utility for certain delivery system studies.
Aclidinium Bromide (CAS 320345-99-1) References
- Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. | Sentellas, S., et al. 2010. Eur J Pharm Sci. 39: 283-90. PMID: 20093184
- Aclidinium bromide abrogates allergen-induced hyperresponsiveness and reduces eosinophilia in murine model of airway inflammation. | Damera, G., et al. 2010. Eur J Pharmacol. 649: 349-53. PMID: 20868661
- Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. | Jones, P. 2013. Adv Ther. 30: 354-68. PMID: 23553509
- Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease. | Woods, JA., et al. 2013. Ann Pharmacother. 47: 1017-28. PMID: 23737515
- Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease. | Babu, KS. and Morjaria, JB. 2015. Ther Adv Respir Dis. 9: 56-68. PMID: 25754881
- Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date. | Moitra, S., et al. 2015. Drug Des Devel Ther. 9: 1989-99. PMID: 25897208
- Aclidinium bromide combined with formoterol inhibits remodeling parameters in lung epithelial cells through cAMP. | Lambers, C., et al. 2015. Pharmacol Res. 102: 310-8. PMID: 26546746
- Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema. | Matera, MG., et al. 2016. Expert Rev Clin Pharmacol. 9: 771-7. PMID: 26998725
- Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: A phase 1, open-label, single-dose study. | Fuhr, R., et al. 2016. Clin Pharmacol Drug Dev. 5: 109-17. PMID: 27138024
- Aclidinium bromide inhibits the growth and metastasis of gastric cancer MKN‑28 cells via the PI3K signaling pathway. | Wang, Y., et al. 2018. Mol Med Rep. 18: 2263-2268. PMID: 29956761
- Aclidinium bromide inhibits proliferation of osteosarcoma cells through regulation of PI3K/Akt pathway. | Li, ZZ., et al. 2019. Eur Rev Med Pharmacol Sci. 23: 105-112. PMID: 30657552
- Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. | D'Urzo, AD., et al. 2019. Ther Adv Respir Dis. 13: 1753466619850725. PMID: 31096854
- Aclidinium Bromide holds promising inhibitory effects in A549 lung cancer cells potentials by regulating PI3K / AKT signaling pathway. | Lin, G., et al. 2019. J BUON. 24: 560-565. PMID: 31128006
- Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update. | D'Urzo, AD., et al. 2021. Expert Rev Respir Med. 15: 1093-1106. PMID: 34137664
- Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial. | Wise, RA., et al. 2021. Adv Ther. 38: 5381-5397. PMID: 34528220
Inhibitor of:
E3BP, mAChR M3, and RSHL3.Activator of:
IL-5, and mAChR M2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Aclidinium Bromide, 100 mg | sc-480200 | 100 mg | $388.00 |